Review
Cells for tissue engineering of cardiac valves
Soumen Jana,
Robert T. Tranquillo,
Amir Lerman,
Soumen Jana
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRobert T. Tranquillo
Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA
Search for more papers by this authorCorresponding Author
Amir Lerman
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
Correspondence to: A. Lerman, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: [email protected]Search for more papers by this author
Soumen Jana,
Robert T. Tranquillo,
Amir Lerman,
Soumen Jana
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
Search for more papers by this authorRobert T. Tranquillo
Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA
Search for more papers by this authorCorresponding Author
Amir Lerman
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA
Correspondence to: A. Lerman, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. E-mail: [email protected]Search for more papers by this authorAbstract
Heart valve tissue engineering is a promising alternative to prostheses for the replacement of diseased or damaged heart valves, because tissue-engineered valves have the ability to remodel, regenerate and grow. To engineer heart valves, cells are harvested, seeded onto or into a three-dimensional (3D) matrix platform to generate a tissue-engineered construct in vitro, and then implanted into a patient's body. Successful engineering of heart valves requires a thorough understanding of the different types of cells that can be used to obtain the essential phenotypes that are expressed in native heart valves. This article reviews different cell types that have been used in heart valve engineering, cell sources for harvesting, phenotypic expression in constructs and suitability in heart valve tissue engineering. Natural and synthetic biomaterials that have been applied as scaffold systems or cell-delivery platforms are discussed with each cell type. Copyright © 2015 John Wiley & Sons, Ltd.
References
- Aicher D, Urbich C, Zeiher A et al. 2007; Endothelial nitric oxide synthase in bicuspid aortic valve disease. Ann Thorac Surg 83: 1290–1294.
- Aleksieva G, Hollweck T, Thierfelder N et al. 2012; Use of a special bioreactor for the cultivation of a new flexible polyurethane scaffold for aortic valve tissue engineering. Biomed Eng Online 11.
- Arcingas E, Ponce L, Hartt Y et al. 2000; Intimal thickening involves transdifferentiation of embryonic endothelial cells. Anat Rec 258: 47–57.
- Armstrong EJ, Bischoff J. 2004; Heart valve development – endothelial cell signaling and differentiation. Circ Res 95: 459–470.
- Asahara T, Masuda H, Takahashi T et al. 1999; Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85: 221–228.
- Asahara T, Murohara T, Sullivan A et al. 1997; Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964–967.
- Ashford TP, Freiman DG. 1968; Platelet aggregation at sites of minimal endothelial injury. An electron microscopic study. Am J Pathol 53: 599–607.
- Barbash IM, Chouraqui P, Baron J et al. 2003; Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108: 863–868.
- Basude S, Hein C, Curtis SL et al. 2012; Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study. Br J Obstet Gynaecol 119: 1008–1013.
- Batten P, McCormack AM, Rose ML et al. 2001; Valve interstitial cells induce donor-specific T-cell anergy. J Thorac Cardiovasc Surg 122: 129–135.
- Benton JA, Deforest CA, Vivekanandan V et al. 2009a; Photocrosslinking of gelatin macromers to synthesize porous hydrogels that promote valvular interstitial cell function. Tissue Eng A 15: 3221–3230.
- Benton JA, Fairbanks BD, Anseth KS. 2009b; Characterization of valvular interstitial cell function in three-dimensional matrix metalloproteinase degradable PEG hydrogels. Biomaterials 30: 6593–6603.
- Bin F, Liu YL, Nin X et al. 2006; Construction of tissue-engineered homograft bioprosthetic heart valves in vitro. Asaio J 52: 303–309.
- Bischoff J, Aikawa E. 2011; Progenitor cells confer plasticity to cardiac valve endothelium. J Cardiovasc Translat Res 4: 710–719.
- Brown XQ, Bartolak-Suki E, Williams C et al. 2010; Effect of substrate stiffness and PDGF on the behavior of vascular smooth muscle cells: implications for atherosclerosis. J Cell Physiol 225: 115–122.
- Butcher JT, Mahler GJ, Hockaday LA. 2011; Aortic valve disease and treatment: the need for naturally engineered solutions. Adv Drug Deliv Rev 63: 242–268.
- Butcher JT, Nerem RM. 2006; Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress. Tissue Eng • 12: 905–915.
- Butcher JT, Nerem RM. 2007; Valvular endothelial cells and the mechanoregulation of valvular pathology. Phil Trans Roy Soc B Biol Sci 362: 1445–1457.
- Camenisch TD, Molin DGM, Person A et al. 2002; Temporal and distinct TGFβ ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 248: 170–181.
- Campbell KM, Johnson CM. 1990; Identification of Staphylococcus aureus binding proteins on isolated porcine cardiac valve cells. J Lab Clin Med 115: 217–223.
- Cebotari S, Lichtenberg A, Tudorache I et al. 2006; Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 114: I132–137.
- Cebotari S, Tudorache I, Schilling T et al. 2010; Heart valve and myocardial tissue engineering. Herz 35: 334–340.
- Chakraborty S, Cheek J, Sakthivel B et al. 2008; Shared gene expression profiles in developing heart valves and osteoblast progenitor cells. Physiol Genom 35: 75–85.
- Chalajour F, Treede H, Ebrahimnejad A et al. 2004; Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp Cell Res 298: 455–464.
- Chambers JB. 2009; Aortic stenosis. Eur J Echocardiogr 10: i11–19.
- Chino F, Kodama A, Otake M et al. 1975; Nonbacterial thrombotic endocarditis in a Japanese autopsy sample. A review of eighty cases. Am Heart J 90: 190–198.
- Chiu JJ, Chien S. 2011; Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 91: 327–387.
- Colazzo F, Chester AH, Taylor PM et al. 2010; Induction of mesenchymal to endothelial transformation of adipose-derived stem cells. J Heart Valve Dis 19: 736–744.
- Colazzo F, Sarathchandra P, Smolenski RT et al. 2011; Extracellular matrix production by adipose-derived stem cells: implications for heart valve tissue engineering. Biomaterials 32: 119–127.
- Combs MD, Yutzey KE. 2009; Heart valve development regulatory networks in development and disease. Circ Res 105: 408–421.
- Cunningham MW. 2004; T cell mimicry in inflammatory heart disease. Mol Immunol 40: 1121–1127.
- Cushing MC, Jaeggli MP, Masters KS et al. 2005a; Serum deprivation improves seeding and repopulation of acellular matrices with valvular interstitial cells. J Biomed Mater Res A 75A: 232–241.
- Cushing MC, Liao JT, Anseth KS. 2005b; Activation of valvular interstitial cells is mediated by transforming growth factor-β1 interactions with matrix molecules. Matrix Biol 24: 428–437.
- Cushing MC, Liao JT, Jaeggli MP et al. 2007; Material-based regulation of the myofibroblast phenotype. Biomaterials 28: 3378–3387.
- Cuy JL, Beckstead BL, Brown CD et al. 2003; Adhesive protein interactions with chitosan: consequences for valve endothelial cell growth on tissue-engineering materials. J Biomed Mater Res A 67A: 538–547.
- D'Arcy JL, Prendergast BD, Chambers JB et al. 2011; Valvular heart disease: the next cardiac epidemic. Heart 97: 91–93.
- Da Costa FDA, Costa ACBA, Prestes R et al. 2010. The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg 90: 1854–1861.
- Davies PF. 1997; Mechanisms involved in endothelial responses to hemodynamic forces. Atherosclerosis 131(suppl): S15–17.
- Davies PF, Tripathi SC. 1993; Mechanical stress mechanisms and the cell. An endothelial paradigm. Circ Res 72: 239–245.
- Deng C, Dong NG, Shi JW et al. 2011; Application of decellularized scaffold combined with loaded nanoparticles for heart valve tissue engineering in vitro. J Huazhong Univ Sci Technol Med Sci 31: 88–93.
- Deppisch LM, Fayemi AO. 1976; Non-bacterial thrombotic endocarditis: clinicopathologic correlations. Am Heart J 92: 723–729.
- Desmouliere A, Badid C, Bochaton-Piallat ML et al. 1997; Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int J Biochem Cell Biol 29: 19–30.
- Dohmen PM, Konertz W. 2009; Tissue-engineered heart valve scaffolds. Ann Thorac Cardiovasc Surg 15: 362–367.
- Dong XC, Wei XF, Yi W et al. 2009; RGD-modified acellular bovine pericardium as a bioprosthetic scaffold for tissue engineering. J Mater Sci Mater Med 20: 2327–2336.
- Drake TA, Pang M. 1989; Effects of interleukin-1, lipopolysaccharide, and streptococci on procoagulant activity of cultured human cardiac valve endothelial and stromal cells. Infect Immun 57: 507–512.
- Duan B, Hockaday LA, Kang KH et al. 2013a; 3D bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. J Biomed Mater Res A 101: 1255–1264.
- Duan B, Hockaday LA, Kang KH et al. 2013b; 3D Bioprinting of heterogeneous aortic valve conduits with alginate/gelatin hydrogels. J Biomed Mater Res A 101A: 1255–1264.
- Dvorin EL, Wylie-Sears J, Kaushal S et al. 2003; Quantitative evaluation of endothelial progenitors and cardiac valve endothelial cells: proliferation and differentiation on poly-glycolic acid/poly-4-hydroxybutyrate scaffold in response to vascular endothelial growth factor and transforming growth factor-β1. Tissue Eng 9: 487–493.
- Eghbali-Fatourechi GZ, Modder UI et al. 2007; Characterization of circulating osteoblast lineage cells in humans. Bone 40: 1370–1377.
- Eisenberg LM, Markwald RR. 1995; Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 77: 1–6.
- Elkins RC, Dawson PE, Goldstein S et al. 2001; Decellularized human valve allografts. Ann Thorac Surg 71: S428–432.
- Emmert MY, Weber B, Wolint P et al. 2012; Stem cell-based transcatheter aortic valve implantation: first experiences in a pre-clinical model. JACC Cardiovasc Interv 5: 874–883.
- Ergun S, Kilic N, Wurmbach JH et al. 2001; Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 4: 193–206.
- Fadel L, Viana BR, Feitosa MLT et al. 2011; Protocols for obtainment and isolation of two mesenchymal stem cell sources in sheep. Acta Cirurg Brasil 26: 267–273.
- Fayet C, Bendeck MP, Gotlieb AI. 2007; Cardiac valve interstitial cells secrete fibronectin and form fibrillar adhesions in response to injury. Cardiovasc Pathol 16: 203–211.
- Fedak PW, Verma S, David TE et al. 2002; Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 106: 900–904.
- Filip DA, Radu A, Simionescu M. 1986; Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells. Circ Res 59: 310–320.
- Flanagan TC, Pandit A. 2003; Living artificial heart valve alternatives: a review. Eur Cells Mater 6: 28–45; discussion, 45.
- Flanagan TC, Wilkins B, Black A et al. 2006; A collagen–glycosaminoglycan co-culture model for heart valve tissue engineering applications. Biomaterials 27: 2233–2246.
- Freeman RV, Otto CM. 2005; Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111: 3316–3326.
- Garcia-Martinez V, Hurle JM. 1986; Cell shape and cytoskeletal organization of the endothelial cells of the semilunar heart valves in the developing chick. Anat Embryol (Berl) 174: 83–89.
- Gawaz M, Brand K, Dickfeld T et al. 2000; Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis Atherosclerosis 148: 75–85.
- Goncalves A, Marcos-Alberca P, Almeria C et al. 2013; Quality of life improvement at midterm follow-up after transcatheter aortic valve implantation. Int J Cardiol 162: 117–122.
- Gong Z, Niklason LE. 2011; Use of human mesenchymal stem cells as alternative source of smooth muscle cells in vessel engineering. Methods Mol Biol 698: 279–294.
- Gould K, Ramirez-Ronda CH, Holmes RK et al. 1975; Adherence of bacteria to heart valves in vitro. J Clin Invest 56: 1364–1370.
- Grauss RW, Hazekamp MG, Oppenhuizen F et al. 2005; Histological evaluation of decellularised porcine aortic valves: matrix changes due to different decellularisation methods. Eur J Cardiothorac Surg 27: 566–571.
- Guerraty M, Mohler ER III. 2007; Models of aortic valve calcification. J Invest Med 55: 278–283.
- Gwanmesia P, Ziegler H, Eurich R et al. 2010; Opposite effects of transforming growth factor-β1 and vascular endothelial growth factor on the degeneration of aortic valvular interstitial cells are modified by the extracellular matrix protein fibronectin: implications for heart valve engineering. Tissue Eng A 16: 3737–3746.
- Gyongyosi M, Lang I, Dettke M et al. 2009; Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat Clin Pract Cardiovasc Med 6: 70–81.
- Hinton RB, Yutzey KE. 2011; Heart valve structure and function in development and disease. Annu Rev Physiol 73: 29–46.
- Hockaday LA, Kang KH, Colangelo NW et al. 2012; Rapid 3D printing of anatomically accurate and mechanically heterogeneous aortic valve hydrogel scaffolds. Biofabrication 4: 035005 (1-10).
- Hoerstrup SP, Kadner A, Breymann C et al. 2002a; Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. Ann Thoracic Surg 74: 46–52.
- Hoerstrup SP, Kadner A, Melnitchouk S et al. 2002b; Tissue engineering of functional trileaflet heart valves from human marrow stromal cells. Circulation 106: I143–150.
- Hoerstrup SP, Sodian R, Daebritz S et al. 2000; Functional living trileaflet heart valves grown in vitro. Circulation 102: 44–49.
- Hoerstrup SP, Zünd G, Lachat M et al. 1998; Tissue engineering: a new approach in cardiovascular surgery – seeding of human fibroblasts on resorbable mesh. Swiss Surg 2: 23–25.
- Hong H, Dong NG, Shi JW et al. 2009a; Fabrication of a novel hybrid heart valve leaflet for tissue engineering: an in vitro study. Artif Organs 33: 554–557.
- Hong H, Dong NG, Shi JW et al. 2009b; Fabrication of a novel hybrid scaffold for tissue engineered heart valve. J Huazhong Univ Sci Technol Med Sci 29: 599–603.
- Ikada Y. 2006; Challenges in tissue engineering. J Roy Soc Interface 3: 589–601.
- Jana S, Tefft BJ, Spoon DB et al. 2014; Scaffolds for tissue engineering of cardiac valves. Acta Biomater 10: 2877–2893.
- Johnson DL, Rose ML, Yacoub MH. 1997; Immunogenicity of human heart valve endothelial cells and fibroblasts. Transpl Proc 29: 984–985.
- Jordan JE, Williams JK, Lee SJ et al. 2012; Bioengineered self-seeding heart valves. J Thorac Cardiovasc Surg 143: 201–208.
- Juthier F, Vincentelli A, Gaudric J et al. 2006; Decellularized heart valve as a scaffold for in vivo recellularization: deleterious effects of granulocyte colony-stimulating factor. J Thorac Cardiovasc Surg 131: 843–852.
- Karam JP, Muscari C, Montero-Menei CN. 2012; Combining adult stem cells and polymeric devices for tissue engineering in infarcted myocardium. Biomaterials 33: 5683–5695.
- Kasimir MT, Rieder E, Seebacher G et al. 2006; Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 15: 278–286; discussion, 286.
- Kasimir MT, Rieder E, Seebacher G et al. 2003; Comparison of different decellularization procedures of porcine heart valves. Int J Artif Organs 26: 421–427.
- Khosla S, Eghbali-Fatourechi GZ. 2006; Circulating cells with osteogenic potential. Ann N Y Acad Sci 1068: 489–497.
- Knight RL, Booth C, Wilcox HE et al. 2005; Tissue engineering of cardiac valves: reseeding of acellular porcine aortic valve matrices with human mesenchymal progenitor cells. J Heart Valve Dis 14: 806–813.
- Konttinen YT, Nykanen P, Nordstrom D et al. 1989; DNA synthesis in prolyl 4-hydroxylase positive fibroblasts in situ in synovial tissue. An autoradiography–immunoperoxidase double labeling study. J Rheumatol 16: 339–345.
- Krebs LT, Xue Y, Norton CR et al. 2000; Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 14: 1343–1352.
- Le Blanc K, Pittenger MF. 2005; Mesenchymal stem cells: progress toward promise. Cytotherapy 7: 36–45.
- Lee TC, Zhao YD, Courtman DW et al. 2000; Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation 101: 2345–2348.
- Li WJ, Cooper JA Jr. 2011; Fibrous scaffolds for tissue engineering. In Biomaterials for Tissue Engineering Applications: A Review of the Past and Future Trends, JA Burdick, RL Mauck (eds). Springer: New York.
10.1007/978-3-7091-0385-2_3 Google Scholar
- Liao J, Joyce EM, Sacks MS. 2008; Effects of decellularization on the mechanical and structural properties of the porcine aortic valve leaflet. Biomaterials 29: 1065–1074.
- Liebner S, Cattelino A, Gallini R et al. 2004; β-Catenin is required for endothelial–mesenchymal transformation during heart cushion development in the mouse. J Cell Biol 166: 359–367.
- Lincoln J, Alfieri CM, Yutzey KE. 2004; Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dynam 230: 239–250.
- Liu AC, Gotlieb AI. 2007; Characterization of cell motility in single heart valve interstitial cells in vitro. Histol Histopathol 22: 873–882.
- Liu AC, Joag VR, Gotlieb AI. 2007; The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 171: 1407–1418.
- Lopez JA, Ross RS, Fishbein MC et al. 1987; Nonbacterial thrombotic endocarditis: a review. Am Heart J 113: 773–784.
- Lukacs NW, Strieter RM, Elner V et al. 1995; Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood 86: 2767–2773.
- Lupu F, Simionescu M. 1985; Organization of the intercellular junctions in the endothelium of cardiac valves. J Submicrosc Cytol 17: 119–132.
- Mantovani A, Bussolino F, Dejana E. 1992; Cytokine regulation of endothelial cell function. FASEB J 6: 2591–2599.
- Marijon E, Ou P, Celermajer DS et al. 2007; Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 357: 470–476.
- Masoumi N, Larson BL, Annabi N et al. 2014; Electrospun PGS:PCL microfibers align human valvular interstitial cells and provide tunable scaffold anisotropy. Adv Healthcare Mater 3: 929–939.
- Meirelles LD, Nardi NB. 2003; Murine marrow-derived mesenchymal stem cells: isolation, in vitro expansion and characterization. Br J Haematol 123: 702–711.
- Mendelson K, Schoen FJ. 2006; Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Engineering 34, 1799–1819.
- Merryman WD, Youn I, Lukoff HD et al. 2006; Correlation between heart valve interstitial cell stiffness and transvalvular pressure: implications for collagen biosynthesis. Am J Physiol Heart Circ Physiol 290: H224–231.
- Messier RH Jr, Bass BL, Aly HM et al. 1994; Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res 57: 1–21.
- Mohamed SA, Radtke A, Sararei R et al. 2012; Locally different endothelial nitric oxide synthase protein levels in ascending aortic aneurysms of bicuspid and tricuspid aortic valve. Cardiol Res Pract 2012; 1–8.
10.1155/2012/165957 Google Scholar
- Mohler ER III. 2000; Are atherosclerotic processes involved in aortic-valve calcification? Lancet 356: 524–525.
- Mohler ER III, Chawla MK, Chang AW et al. 1999; Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8: 254–260.
- Mol A, Smits AIPM, Bouten CVC et al. 2009; Tissue engineering of heart valves: advances and current challenges. Expert Rev Med Devices 6: 259–275.
- Mulholland DL, Gotlieb AI. 1996; Cell biology of valvular interstitial cells. Can J Cardiol 12: 231–236.
- Nair PD, Janet C, Giachelli CM et al. 2002; Biodegradable amino acid–hydrogel porous scaffold for the tissue engineering of the heart valve. In Proceedings of the Second Joint EMBSBMES Conference, Nair PD (ed.), IEEE, Houston, TX, USA, 2002; 856–857.
- Narine K, Dewever O, Cathenis K et al. 2004; Transforming growth factor-β-induced transition of fibroblasts: a model for myofibroblast procurement in tissue valve engineering. J Heart Valve Dis 13: 281–289.
- Neidert MR, Tranquillo RT. 2006; Tissue-engineered valves with commissural alignment. Tissue Eng 12: 891–903.
- Nishimura RA. 2002; Cardiology patient pages. Aortic valve disease. Circulation 106: 770–772.
- Nombela-Arrieta C, Ritz J, Silberstein LE. 2011; The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 12: 126–131.
- Nuttelman CR, Henry SM, Anseth KS. 2002; Synthesis and characterization of photocrosslinkable, degradable poly(vinyl alcohol)-based tissue engineering scaffolds. Biomaterials 23: 3617–3626.
- O'Brien KD, Reichenbach DD, Marcovina SM et al. 1996; Apolipoproteins B, α and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thrombos Vasc Biol 16: 523–532.
- O'Brien MF, Goldstein S, Walsh S et al. 1999; The SynerGraft valve: a new acellular (nonglutaraldehyde-fixed) tissue heart valve for autologous recellularization first experimental studies before clinical implantation. Semin Thorac Cardiovasc Surg 11: 194–200.
- Olsson M, Thyberg J, Nilsson J. 1999; Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thrombos Vasc Biol 19: 1218–1222.
- Ota T, Sawa Y, Iwai S et al. 2005; Fibronectin-hepatocyte growth factor enhances re-endothelialization in tissue-engineered heart valve. Ann Thorac Surg 80: 1794–1802.
- Ouyang H, Zhang JB, Liu Y et al. 2008; Research on application of modified polyethylene glycol hydrogels in the construction of tissue engineered heart valve. Chin J Surg 46: 1723–1726.
- Pace NL, Horton W. 1975; Indwelling pulmonary artery catheters: their relationship to aspetic thrombotic endocardial vegetations. J Am Med Assoc 233: 893–894.
- Padala M, Keeling WB, Guyton RA et al. 2011; Innovations in therapies for heart valve disease. Circ J 75: 1028–1041.
- Paranya G, Vineberg S, Dvorin E et al. 2001; Aortic valve endothelial cells undergo transforming growth factor-β-mediated and non-transforming growth factor-β-mediated transdifferentiation in vitro. Am J Pathol 159: 1335–1343.
- Perin EC, Lopez J. 2006; Methods of stem cell delivery in cardiac diseases. Nat Clin Pract Cardiovasc Med 3(suppl 1): S110–113.
- Perry TE, Kaushal S, Sutherland FWH et al. 2003; Bone marrow as a cell source for tissue engineering heart valves. Ann Thorac Surg 75: 761–767.
- Person AD, Klewer SE, Runyan RB. 2005; Cell biology of cardiac cushion development. Int Rev Cytol 243: 287–335.
- Poggio P, Sainger R, Branchetti E et al. 2013; Noggin attenuates the osteogenic activation of human valve interstitial cells in aortic valve sclerosis. Cardiovasc Res 98: 402–10.
- Pucéat M. 2013; Embryological origin of the endocardium and derived valve progenitor cells: from developmental biology to stem cell-based valve repair. Biochim Biophys Acta 1833: 917–922.
- Quinlan AMT, Billiar KL. 2012; Investigating the role of substrate stiffness in the persistence of valvular interstitial cell activation. J Biomed Mater Res A 100A: 2474–2482.
- Rabkin-Aikawa E, Farber M, Aikawa M et al. 2004; Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis 13: 841–847.
- Rabkin E, Aikawa M, Stone JR et al. 2001; Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104: 2525–2532.
- Rabkin SW, Lodhia P, Luong MW. 2009; P38 MAP kinase in valve interstitial cells is activated by angiotensin II or nitric oxide/peroxynitrite, but reduced by Toll-like receptor-2 stimulation. J Heart Valve Dis 18: 653–661.
- Ramajamannan NM. 2009; Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler Thromb Vasc Biol 29: 162–168.
- Ramaswamy S, Gottlieb D, Engelmayr GC et al. 2010; The role of organ level conditioning on the promotion of engineered heart valve tissue development in vitro using mesenchymal stem cells. Biomaterials 31: 1114–1125.
- Roberts S, Kosanke S, Terrence Dunn S et al. 2001; Pathogenic mechanisms in rheumatic carditis: focus on valvular endothelium. J Infect Dis 183: 507–511.
- Robinson PS, Tranquillo RT. 2009; Planar biaxial behavior of fibrin-based tissue-engineered heart valve leaflets. Tissue Eng A 15: 2763–2772.
- Rowley KM, Clubb KS, Smith GJ et al. 1984; Right-sided infective endocarditis as a consequence of flow-directed pulmonary-artery catheterization. A clinicopathological study of 55 autopsied patients. N Engl J Med 311: 1152–1156.
- Roy A, Brand NJ, Yacoub MH. 2000; Molecular characterization of interstitial cells isolated from human heart valves. J Heart Valve Dis 9: 459–464; discussion, 464–465.
- Sacks MS, Yoganathan AP. 2007; Heart valve function: a biomechanical perspective. Phil Trans R Soc B Biol Sci 362: 1369–1391.
- Sales VL, Mettler BA, Engelmayr GC et al. 2010; Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng A 16: 257–267.
- Sant S, Iyer D, Gaharwar AK et al. 2012; Effect of biodegradation and de novo matrix synthesis on the mechanical properties of valvular interstitial cell-seeded polyglycerol sebacate-polycaprolactone scaffolds. Acta Biomater 9: 5963–5973.
- Sarraf CE, Harris AB, McCulloch AD et al. 2005; Cell proliferation rates in an artificial tissue-engineered environment. Cell Prolif 38: 215–221.
- Sarugaser R, Lickorish D, Baksh D et al. 2005; Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells 23, 220–229.
- Schenke-Layland K, Vasilevski O, Opitz F et al. 2003; Impact of decellularization of xenogeneic tissue on extracellular matrix integrity for tissue engineering of heart valves. J Struct Biol 143, 201–208.
- Schmidt D, Achermann J, Odermatt B et al. 2007; Prenatally fabricated autologous human living heart valves based on amniotic fluid-derived progenitor cells as single cell source. Circulation 116: I64–70.
- Schmidt D, Achermann J, Odermatt B et al. 2008; Cryopreserved amniotic fluid-derived cells: a lifelong autologous fetal stem cell source for heart valve tissue engineering. J Heart Valve Dis 17: 446–455; discussion, 455.
- Schmidt D, Breymann C, Weber A et al. 2004; Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts. Ann Thorac Surg 78: 2094–2098.
- Schmidt D, Dijkman PE, Driessen-Mol A et al. 2010; Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 56: 510–520.
- Schmidt D, Mol A, Breymann C et al. 2006a; Living autologous heart valves engineered from human prenatally harvested progenitors. Circulation 114: I125–131.
- Schmidt D, Mol A, Odermatt B et al. 2006b; Engineering of biologically active living heart valve leaflets using human umbilical cord-derived progenitor cells. Tissue Eng 12, 3223–3232.
- Schnell AM, Hoerstrup SP, Zund G et al. 2001; Optimal cell source for cardiovascular tissue engineering: venous vs aortic human myofibroblasts. Thorac Cardiovasc Surg 49: 221–225.
- Segura AM, Luna RE, Horiba K et al. 1998; Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation 98: II331–337; discussion, II337–338.
- Shelton EL, Yutzey KE. 2007; Tbx20 regulation of endocardial cushion cell proliferation and extracellular matrix gene expression. Dev Biol 302: 376–388.
- Sherman W, Martens TP, Viles-Gonzalez JF et al. 2006; Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med 3(suppl 1): S57–64.
- Shi Y, Ramamurthi A, Vesely I. 2002; Towards tissue engineering of a composite aortic valve. Biomed Sci Instrument 38: 35–40.
- Shinoka T, Breuer CK, Tanel RE et al. 1995; Tissue engineering heart valves: valve leaflet replacement study in a lamb model. Ann Thorac Surg 60: S513–516.
- Simionescu DT, Chen J, Jaeggli M et al. 2012; Form follows function: advances in trilayered structure replication for aortic heart valve tissue engineering. J Healthcare Eng 3: 179–202.
- Simmons CA, Grant GR, Manduchi E et al. 2005; Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res 96: 792–799.
- Simon A, Zavazava N, Sievers HH et al. 1993. In vitro cultivation and immunogenicity of human cardiac valve endothelium. J Cardiac Surg 8: 656–665.
- Smith S, Taylor PM, Chester AH et al. 2007; Force generation of different human cardiac valve interstitial cells: relevance to individual valve function and tissue engineering. J Heart Valve Dis 16: 440–446.
- Sodian R, Schaefermeier P, Abegg-Zips S et al. 2010; Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg 89: 819–828.
- Somers P, Cornelissen R, Thierens H et al. 2012; An optimized growth factor cocktail for ovine mesenchymal stem cells. Growth Factors 30: 37–48.
- Stamm C, Khosravi A, Grabow N et al. 2004; Biomatrix/polymer composite material for heart valve tissue engineering. Ann Thorac Surg 78: 2084–2092.
- Stock UA, Nagashima M, Khalil PN et al. 2000; Tissue-engineered valved conduits in the pulmonary circulation. J Thorac Cardiovasc Surg 119: 732–740.
- Sumpio BE, Riley JT, Dardik A. 2002; Cells in focus: endothelial cell. Int J Biochem Cell Biol 34: 1508–1512.
- Sutherland FW, Perry TE, Yu Y et al. 2005; From stem cells to viable autologous semilunar heart valve. Circulation 111: 2783–2791.
- Sy JC, Davis ME. 2010; Delivering regenerative cues to the heart: cardiac drug delivery by microspheres and peptide nanofibers. J Cardiovasc Transl Res 3: 461–468.
- Syedain ZH, Bradee AR, Kren S et al. 2013; Decellularized tissue-engineered heart valve leaflets with recellularization potential. Tissue Eng A 19: 759–769.
- Syedain ZH, Meier LA, Lahti MT et al. 2014; Implantation of completely biological engineered grafts following decellularization into the sheep femoral artery. Tissue Eng A 20: 1726–1734.
- Syedain ZH, Meier LA, Reimer JM et al. 2013; Tubular heart valves from decellularized engineered tissue. Ann Biomed Eng 41: 2645–2654.
- Takahaski K, Yamanaka S. 2006; Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676.
- Takkenberg JJ, Rajamannan NM, Rosenhek R et al. 2008; The need for a global perspective on heart valve disease epidemiology. The SHVD Working Group on Epidemiology of Heart Valve Disease founding statement. J Heart Valve Dis 17: 135–139.
- Tao G, Kotick JD, Lincoln J. 2012; Heart valve development, maintenance and disease: the role of endothelial cells. Curr TOP Dev Biol 100: 203–232.
- Taylor PA, Batten P, Brand NJ et al. 2003; The cardiac valve interstitial cell. Int J Biochem Cell Biol 35: 113–118.
- Tekstra J, Beekhuisen H, Van de Gevel JS et al. 1999; Infection of human endothelial cells with Staphylococcus aureus induces the production of monocyte chemotactic protein-1 (MCP-1) and monocyte chemotaxis. Clin Exp Immunol 117: 489–495.
- Van Vlierberghe S, Dubruel P, Schacht E. 2011; Biopolymer-based hydrogels as scaffolds for tissue engineering applications: a review. Biomacromolecules 12: 1387–1408.
- Veinot JP. 2006; Pathology of inflammatory native valvular heart disease. Cardiovasc Pathol 15: 243–251.
- Vesely I. 2005; Heart valve tissue engineering. Circ Res 97: 743–755.
- Walker GA, Masters KS, Shah DN et al. 2004; Valvular myofibroblast activation by transforming growth factor-β: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95: 253–260.
- Wang H, Haeger SM, Kloxin AM et al. 2012; Redirecting valvular myofibroblasts into dormant fibroblasts through light-mediated reduction in substrate modulus. PLoS One 7: e39969.
- Wang HS, Hung SC, Peng ST et al. 2004; Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 22: 1330–1337.
- Weber B, Emmert MY, Behr L et al. 2012; Prenatally engineered autologous amniotic fluid stem cell-based heart valves in the fetal circulation. Biomaterials 33: 4031–4043.
- Wilson W, Taubert KA, Gewitz M et al. 2007; Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 116: 1736–1754.
- Wylie-Sears J, Aikawa E, Levine RA et al. 2011; Mitral valve endothelial cells with osteogenic differentiation potential. Arterioscler Thromb Vasc Biol 31: 598–U266.
- Xu S, Liu AC, Kim H et al. 2012; Cell density regulates in vitro activation of heart valve interstitial cells. Cardiovasc Pathol 21: 65–73.
- Ye XF, Wang HZ, Zhou JX et al. 2013; The effect of heparin–VEGF multilayers on the biocompatibility of decellularized aortic valve with platelets and endothelial progenitor cells. Plos One 8: e54622 (1-10).
- Zannettino AC, Holding CA, Diamond P et al. 2005; Osteoprotegerin (OPG) is localized to the Weibel–Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204: 714–723.
- Zhang Y, Zhou P, Pan LF et al. 2007; Growth of human smooth muscle cells on the silk fibroin-modified polyhydroxyalkanoate scaffold. Acta Chim Sinica 65: 2935–2940.
- Zhao DE, Li RB, Liu WY et al. 2003; Tissue-engineered heart valve on acellular aortic valve scaffold: in vivo study. Asian Cardiovasc Thorac Ann 11: 153–156.
- Zund G, Hoerstrup SP, Schoeberlein A et al. 1998; Tissue engineering: a new approach in cardiovascular surgery; seeding of human fibroblasts followed by human endothelial cells on resorbable mesh. Eur J Cardiothorac Surg 13: 160–164.
